• Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~11% in the premarket on Friday after announcing plans to eliminate its commercial operations in a bid to generate as much as $100M in cost savings next year.
• The decision follows the FDA’s rejection of the company’s New Drug Application (NDA) for diabetes therapy, Zynquista (sotagliflozin), based on deficiencies found in the NDA.
• Accordingly, Lexicon’s (NASDAQ:LXRX) commercial field team will be axed, and 60% of the company’s workforce will lose their jobs.
• The size of the company’s other functions will also be reduced, and all ongoing and planned promotional efforts for its commercialized drugs, Inpefa and Zynquista, will also come to an end. Through the program, Lexicon (LXRX) plans to cut its 2025 operating costs by $100M.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。